Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07516847) titled 'Dapagliflozin for Anemia in Lower-Risk Myelodysplastic Syndromes' on April 1.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Seug yun Yoon, MD

Condition: Myelodysplastic Syndromes (MDS) Anemia

Intervention: Drug: Dapagliflozin (10mg Tab)

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: September 2026

Target Sample Size: 37

To know more, visit https://clinicaltrials.gov/study/NCT07516847

Published by HT Digital Content Services with permission from...